aspirin has been researched along with Smoking Cessation in 110 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Smoking Cessation: Discontinuing the habit of SMOKING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the association between CDS tools and racial and sex disparities in the aspirin use, blood pressure control, cholesterol management, and smoking cessation (ABCS) care quality metrics among smaller primary care practices." | 8.31 | Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex. ( Atem, FD; Balasubramanian, BA; Marino, M; Roberts, MM; Wells, R, 2023) |
| " We now investigate if initiation of treatment with SSRIs, statins, clopidogrel, aspirin or oral anticoagulants and smoking cessation impacts coated-platelet levels at 90 days after ischemic stroke." | 7.96 | Clopidogrel use and smoking cessation result in lower coated-platelet levels after stroke. ( Dale, GL; Kirkpatrick, AC; Prodan, CI; Vincent, AS, 2020) |
| "The Healthy Hearts in the Heartland (H3) study is part of a nationwide effort, EvidenceNOW, seeking to better understand the ability of small primary care practices to improve "ABCS" clinical quality measures: appropriate Aspirin therapy, Blood pressure control, Cholesterol management, and Smoking cessation." | 5.27 | Design of healthy hearts in the heartland (H3): A practice-randomized, comparative effectiveness study. ( Brown, T; Chung, I; Ciolino, JD; Jackson, KL; Kho, AN; Liss, DT; Murakami, L; Persell, SD; Walunas, TL, 2018) |
| " There is general consensus between guidelines (at least 4 of 6 guidelines in agreement) in early pregnancy risk selection, and use of low-dose aspirin for women with major risk factors for placental insufficiency." | 4.98 | Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. ( Anderson, NH; Figueras, F; McCowan, LM, 2018) |
| " If alternative interventions, such as smoking cessation or low-dose aspirin treatment were included in the analysis, statin therapy became less cost-effective." | 4.85 | Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. ( De Laet, C; Franco, O; Neyt, M; Ramaekers, D; Van Brabandt, H, 2009) |
| " Over the 10 to 15 years after clinical diagnosis, tight glycemic control probably reduces the risk for blindness and end-stage renal disease, and aggressive control of hypertension, lipid therapy, and aspirin use reduce cardiovascular events." | 4.82 | Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. ( Donahue, K; Frame, P; Harris, R; Lohr, KN; Rathore, SS; Woolf, SH, 2003) |
| " Strategies used for plaque stabilisation resulting in a reduction in cardiovascular mortality and morbidity are: smoking cessation; aspirin (acetylsalicylic acid); blood pressure control; lipid lowering agents when low density lipoprotein cholesterol is elevated despite dietary therapy; coronary bypass surgery in patients with left main stem disease or triple vessel coronary disease and diminished left ventricular function; and use of estrogen in postmenopausal women." | 4.80 | Choosing the most appropriate treatment for stable angina. Safety considerations. ( Asirvatham, S; Sebastian, C; Thadani, U, 1998) |
| " Smoking cessation, increased physical activity and lipid lowering are key lifestyle objectives, while beta blockade and aspirin should be routinely prescribed for all patients following acute myocardial infarction, unless there are specific contraindications." | 4.79 | What do we really know about secondary prevention after myocardial infarction? ( Wielgosz, AT, 1995) |
| " The eight regimens that meet these criteria are prophylactic aspirin therapy, estrogen replacement therapy, nicotine substitutes as adjunctive therapy in smoking cessation, beta-blocker therapy following myocardial infarction, anti-inflammatory agents in the treatment of asthma, antidepressant drugs as therapy for mild depression, increased fiber intake and regular exercise." | 4.79 | Eight underused prescriptions. ( Kerr, CP, 1994) |
| "To evaluate the association between CDS tools and racial and sex disparities in the aspirin use, blood pressure control, cholesterol management, and smoking cessation (ABCS) care quality metrics among smaller primary care practices." | 4.31 | Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex. ( Atem, FD; Balasubramanian, BA; Marino, M; Roberts, MM; Wells, R, 2023) |
| " We now investigate if initiation of treatment with SSRIs, statins, clopidogrel, aspirin or oral anticoagulants and smoking cessation impacts coated-platelet levels at 90 days after ischemic stroke." | 3.96 | Clopidogrel use and smoking cessation result in lower coated-platelet levels after stroke. ( Dale, GL; Kirkpatrick, AC; Prodan, CI; Vincent, AS, 2020) |
| " Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation." | 3.85 | Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017) |
| " We measured prescription rates of evidence-based recommended therapies after ACS including reasons for nonprescription of aspirin, statins, β-blockers, angiotensin converting-enzyme inhibitors (ACEI) / angiotensin II receptor blockers (ARB), along with cardiac rehabilitation attendance and delivery of a smoking cessation intervention." | 3.83 | Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland. ( Auer, R; Cornuz, J; Gencer, B; Mach, F; Matter, CM; Muller, O; Nanchen, D; Rodondi, N; Welker, J; Windecker, S, 2016) |
| "By using data from the Get With The Guidelines-Coronary Artery Disease registry, we compared adherence to 6 performance measures (aspirin within 24 hours, discharge on aspirin, discharge on beta-blockers, patients with low ejection fraction discharged on angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, smoking cessation counseling, and use of lipid-lowering medications) in eligible patients with coronary artery disease who underwent coronary artery bypass graft surgery, percutaneous coronary intervention, or no intervention between 2003 and 2008." | 3.81 | Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. ( Bhatt, DL; Cannon, CP; Deedwania, P; Fonarow, GC; Grau-Sepulveda, M; Hernandez, AF; Kumbhani, DJ; Laskey, WK; Peacock, WF; Peterson, ED; Schwamm, LH, 2015) |
| "Current guidelines recommend that patients with peripheral arterial disease (PAD) cease smoking and be treated with aspirin, statin medications, and angiotensin-converting enzyme (ACE) inhibitors." | 3.80 | Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Bang, H; Chen, DC; Laird, JR; McCoach, CE; Singh, S; Westin, GG; Yeo, KK, 2014) |
| "Good evidence exists to support the use of secondary prevention medications (aspirin, statins, beta-blockers and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)) and smoking cessation in patients after acute coronary syndromes (ACSs)." | 3.80 | Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective. ( Griffiths, B; Lesosky, M; Ntsekhe, M, 2014) |
| " Aggressive medical management was defined as aspirin plus clopidogrel therapy for a minimum of 3 months, blood pressure control, statin use with a low-density lipoprotein (LDL) goal of <70 mg/dL, smoking cessation, and body mass index <25 kg/m(2)." | 3.79 | Early aggressive medical management for patients with symptomatic intracranial stenosis. ( Ayala, L; Cawley, CM; Dion, JE; Frankel, MR; Hammonds, LP; Kingston, C; Mitchell, B; Nahab, F; Tong, FC, 2013) |
| " Reported compliance with AMI performance measures was analyzed using data from the United States Department of Health and Human Services Hospital Compare Web site from 2007, including aspirin administration, beta-blocker administration, angiotensin-converting enzyme or angiotensin receptor blocking agents, and smoking cessation counseling." | 3.76 | Hospitals with percutaneous coronary intervention capability have greater adherence to established myocardial infarction guidelines. ( Chiang, J; Kao, J; Patel, V; Schopfer, D, 2010) |
| "Our results conclude that 10% decrease in body mass index (BMI) among overweight patients, smoking cessation, initiation to undertake a preventive treatment with low-dose aspirin, initiation to undertake or intensify blood pressure control, initiation to undertake or intensify lipidic control, and shift to biguanides among overweight patients are factors associated with significant benefits (avoided costs) which compensate for the increase in treatment costs." | 3.73 | [Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. ( Crainich, D; Lebrun, T; Marissal, JP; Sailly, JC, 2005) |
| " Patients and providers can then examine the effect of introducing one or more risk-reducing interventions (aspirin, lipid-lowering drug therapy, antihypertensive medication, or smoking cessation) on the patient's CHD risk." | 3.72 | Heart to Heart: a computerized decision aid for assessment of coronary heart disease risk and the impact of risk-reduction interventions for primary prevention. ( Kuo, J; Lee, YZ; Mulrow, C; Phillips, C; Pignone, M; Sheridan, SL; Zeiger, R, 2004) |
| " Proportional hazard models compared the association between mental disorders and mortality before and after adjusting 5 established quality indicators: reperfusion, aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and smoking cessation counseling." | 3.71 | Quality of medical care and excess mortality in older patients with mental disorders. ( Bradford, WD; Druss, BG; Krumholz, HM; Radford, MJ; Rosenheck, RA, 2001) |
| "Conservative treatment of coronary heart disease is the therapeutic mainstay and includes various measures aimed at achieving a general reduction of risks." | 2.43 | [Conservative treatment of coronary heart disease--current options]. ( Desch, S; Niebauer, J; Schuler, G, 2005) |
| "Aspirin is the treatment of choice for stroke prevention in patients who do not require anticoagulation." | 2.42 | Transient ischemic attacks: Part II. Treatment. ( Solenski, NJ, 2004) |
| "Stroke is a major cause of morbidity and mortality." | 2.41 | A benefit-risk assessment of agents used in the secondary prevention of stroke. ( MacWalter, RS; Shirley, CP, 2002) |
| "Patients with type 2 diabetes have a high risk of morbidity and premature mortality from cardiovascular disease." | 2.41 | [Prevention of cardiovascular disease in type 2 diabetes]. ( Birkeland, KI; Claudi, T; Hanssen, KF; Hansteen, V; Hjermann, I; Jenssen, T; Jervell, J; Os, I, 2000) |
| "The diagnosis of cerebral thromboangiitis obliterans in life is facilitated by modern neuroimaging and should prompt immediate cessation of smoking and a search for an underlying prothrombotic tendency." | 1.38 | Revisiting cerebral thromboangiitis obliterans. ( Anderson, C; Barnett, M; Barnett, Y; Brennan, J; Buckland, ME; Hurelbrink, CB; Leicester, J; Wilkinson, M, 2012) |
| "Peripheral arterial disease is a manifestation of systemic atherosclerosis and is predictive of future cardiovascular events." | 1.38 | The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions. ( Ardati, AK; Aronow, HD; Bove, PG; Grossman, PM; Gurm, HS; Kaufman, SR; Nypaver, TJ, 2012) |
| "Buerger's disease or Thromboangiitis obliterans is a segmental inflammatory disease that affects the vessels and nerves of the extremities." | 1.37 | Buerger's disease (Thromboangiitis obliterans): a diagnostic challenge. ( Araújo, AC; Jorge, VC; Noronha, C; Panarra, A; Riso, N; Vaz Riscado, M, 2011) |
| "Aspirin was used in 64% of patients with CAD and in 28." | 1.35 | Control of cardiovascular risk factors and use of aspirin in diabetic patients remain elusive. ( Garg, P; Jeevanantham, V; Khan, A; Nautiyal, A; Reddy, PC; Shrivastava, R, 2008) |
| "Buerger's disease or thromboangiitis obliterans is a disorder of unknown etiology which affects young heavy smokers, mainly of male sex; it is not clear why this disease afflicts only a little number of heavy smokers." | 1.31 | [Aspects of thrombophilia in Buerger's disease]. ( Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A; Volpe, A, 2000) |
| "If intermittent claudication is present, angiography of the pelvis and legs then follows." | 1.31 | [Peripheral arterial occlusive disease. Symptoms, basic diagnosis and staged therapy]. ( Grothe, A; Kettmann, R; Welter, HF, 2002) |
| "Treatment with aspirin, beta blockers, and angiotensin converting enzyme inhibitors." | 1.30 | Secondary prevention in coronary heart disease: baseline survey of provision in general practice. ( Campbell, NC; Deans, HG; Rawles, JM; Ritchie, LD; Thain, J, 1998) |
| "The value of treatment of hyperlipidemia in reducing the incidence of a first stroke remains to be demonstrated." | 1.28 | Ischemic stroke. How to keep the first one from happening. ( Bundlie, SR, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (21.82) | 18.2507 |
| 2000's | 48 (43.64) | 29.6817 |
| 2010's | 32 (29.09) | 24.3611 |
| 2020's | 6 (5.45) | 2.80 |
| Authors | Studies |
|---|---|
| Roberts, MM | 1 |
| Marino, M | 1 |
| Wells, R | 1 |
| Atem, FD | 1 |
| Balasubramanian, BA | 1 |
| Shelley, DR | 1 |
| Gepts, T | 1 |
| Siman, N | 2 |
| Nguyen, AM | 1 |
| Cleland, C | 2 |
| Cuthel, AM | 1 |
| Rogers, ES | 1 |
| Ogedegbe, O | 1 |
| Pham-Singer, H | 1 |
| Wu, W | 2 |
| Berry, CA | 1 |
| Richards, A | 1 |
| Jackson, NJ | 1 |
| Cheng, EM | 1 |
| Bryg, RJ | 1 |
| Brown, A | 1 |
| Towfighi, A | 1 |
| Sanossian, N | 1 |
| Barry, F | 1 |
| Li, N | 1 |
| Vickrey, BG | 1 |
| Ambrose, JA | 1 |
| Najafi, A | 1 |
| Jain, V | 1 |
| Muller, JE | 1 |
| Ranka, S | 1 |
| Barua, RS | 1 |
| Pandey, A | 1 |
| Golwala, H | 1 |
| Hall, HM | 1 |
| Wang, TY | 2 |
| Lu, D | 1 |
| Xian, Y | 1 |
| Chiswell, K | 1 |
| Joynt, KE | 1 |
| Goyal, A | 1 |
| Das, SR | 1 |
| Kumbhani, D | 1 |
| Julien, H | 1 |
| Fonarow, GC | 3 |
| de Lemos, JA | 2 |
| Galyfos, G | 1 |
| Kerasidis, S | 1 |
| Kastrisios, G | 1 |
| Giannakakis, S | 1 |
| Sachmpazidis, I | 1 |
| Anastasiadou, C | 1 |
| Geropapas, G | 1 |
| Papapetrou, A | 1 |
| Papacharalampous, G | 1 |
| Maltezos, C | 1 |
| McCowan, LM | 1 |
| Figueras, F | 1 |
| Anderson, NH | 1 |
| Shelley, D | 1 |
| Blechter, B | 1 |
| Jiang, N | 1 |
| Ogedegbe, G | 1 |
| Williams, S | 1 |
| Rogers, E | 1 |
| Berry, C | 1 |
| Ciolino, JD | 1 |
| Jackson, KL | 1 |
| Liss, DT | 1 |
| Brown, T | 1 |
| Walunas, TL | 1 |
| Murakami, L | 1 |
| Chung, I | 1 |
| Persell, SD | 1 |
| Kho, AN | 1 |
| Govindaswami, B | 1 |
| Jegatheesan, P | 1 |
| Nudelman, M | 1 |
| Narasimhan, SR | 1 |
| Bittner, V | 1 |
| Kirkpatrick, AC | 1 |
| Vincent, AS | 1 |
| Dale, GL | 1 |
| Prodan, CI | 1 |
| Smith, L | 1 |
| Cruickshank, R | 1 |
| Beattie, D | 1 |
| Burkes, M | 1 |
| Armstrong, EJ | 2 |
| Chen, DC | 2 |
| Westin, GG | 1 |
| Singh, S | 1 |
| McCoach, CE | 1 |
| Bang, H | 1 |
| Yeo, KK | 1 |
| Anderson, D | 1 |
| Amsterdam, EA | 2 |
| Laird, JR | 2 |
| Griffiths, B | 1 |
| Lesosky, M | 1 |
| Ntsekhe, M | 1 |
| Jagpal, S | 1 |
| Pistun, O | 1 |
| Mikhail, J | 1 |
| Kumbhani, DJ | 1 |
| Cannon, CP | 2 |
| Hernandez, AF | 2 |
| Peterson, ED | 2 |
| Peacock, WF | 1 |
| Laskey, WK | 1 |
| Deedwania, P | 1 |
| Grau-Sepulveda, M | 1 |
| Schwamm, LH | 1 |
| Bhatt, DL | 1 |
| Joseph, JM | 1 |
| Johnson, PJ | 1 |
| Wholey, DR | 1 |
| Frederick, ML | 1 |
| Singh, GD | 1 |
| Muehlenberg, K | 1 |
| Metzler, C | 1 |
| Pech, O | 1 |
| Welker, J | 1 |
| Auer, R | 1 |
| Gencer, B | 1 |
| Muller, O | 1 |
| Cornuz, J | 1 |
| Matter, CM | 1 |
| Mach, F | 1 |
| Windecker, S | 1 |
| Rodondi, N | 1 |
| Nanchen, D | 1 |
| Harrison, RW | 1 |
| Simon, D | 1 |
| Miller, AL | 1 |
| Neyt, M | 1 |
| De Laet, C | 1 |
| Van Brabandt, H | 1 |
| Franco, O | 1 |
| Ramaekers, D | 1 |
| Richard, E | 1 |
| Kuiper, R | 1 |
| Dijkgraaf, MG | 1 |
| Van Gool, WA | 1 |
| Campbell-Scherer, DL | 1 |
| Green, LA | 1 |
| Cosio, BG | 1 |
| Soriano, JB | 1 |
| Cooney, MT | 1 |
| Dudina, A | 1 |
| Whincup, P | 1 |
| Capewell, S | 2 |
| Menotti, A | 1 |
| Jousilahti, P | 1 |
| Njølstad, I | 1 |
| Oganov, R | 1 |
| Thomsen, T | 1 |
| Tverdal, A | 1 |
| Wedel, H | 1 |
| Wilhelmsen, L | 1 |
| Graham, I | 1 |
| Lewis, WR | 1 |
| Ellrodt, AG | 1 |
| Peterson, E | 1 |
| LaBresh, KA | 1 |
| Pan, W | 1 |
| Olomu, AB | 1 |
| Grzybowski, M | 1 |
| Ramanath, VS | 1 |
| Rogers, AM | 1 |
| Vautaw, BM | 1 |
| Chen, B | 1 |
| Roychoudhury, C | 1 |
| Jackson, EA | 1 |
| Eagle, KA | 2 |
| Gross, H | 1 |
| Schopfer, D | 1 |
| Patel, V | 1 |
| Chiang, J | 1 |
| Kao, J | 1 |
| Hankey, GJ | 2 |
| Nahab, F | 1 |
| Kingston, C | 1 |
| Frankel, MR | 1 |
| Dion, JE | 1 |
| Cawley, CM | 1 |
| Mitchell, B | 1 |
| Hammonds, LP | 1 |
| Ayala, L | 1 |
| Tong, FC | 1 |
| Gohlke, H | 1 |
| Sacco, RL | 1 |
| Frieden, TR | 1 |
| Blakeman, DE | 1 |
| Jauch, EC | 1 |
| Mohl, S | 1 |
| Grassin-Delyle, S | 1 |
| Girodet, PO | 1 |
| Hurelbrink, CB | 1 |
| Barnett, Y | 1 |
| Buckland, ME | 1 |
| Wilkinson, M | 1 |
| Leicester, J | 1 |
| Anderson, C | 1 |
| Brennan, J | 1 |
| Barnett, M | 1 |
| Swarbrick, M | 1 |
| Fitzgerald, C | 1 |
| Jorge, VC | 1 |
| Araújo, AC | 1 |
| Noronha, C | 1 |
| Panarra, A | 1 |
| Riso, N | 1 |
| Vaz Riscado, M | 1 |
| Bikdeli, B | 1 |
| Barreto-Filho, JA | 1 |
| Drozda, JP | 1 |
| Holmes, DP | 1 |
| Wright, JS | 1 |
| Wall, HK | 1 |
| Briss, PA | 1 |
| Schooley, M | 1 |
| Darshan, J | 1 |
| Shaw, E | 1 |
| Green, B | 1 |
| Gallagher, PJ | 1 |
| Gadola, SD | 1 |
| Ardati, AK | 1 |
| Kaufman, SR | 1 |
| Aronow, HD | 1 |
| Nypaver, TJ | 1 |
| Bove, PG | 1 |
| Gurm, HS | 1 |
| Grossman, PM | 1 |
| Welter, HF | 1 |
| Kettmann, R | 1 |
| Grothe, A | 1 |
| Murphy, M | 2 |
| Foster, C | 2 |
| Sudlow, C | 2 |
| Nicholas, J | 2 |
| Mulrow, C | 3 |
| Ness, A | 2 |
| Pignone, M | 3 |
| MacWalter, RS | 1 |
| Shirley, CP | 1 |
| Czuriga, I | 1 |
| Levenson, D | 2 |
| Harris, R | 1 |
| Donahue, K | 1 |
| Rathore, SS | 1 |
| Frame, P | 1 |
| Woolf, SH | 1 |
| Lohr, KN | 1 |
| Brown, AF | 1 |
| Mangione, CM | 1 |
| Saliba, D | 1 |
| Sarkisian, CA | 1 |
| Akosah, KO | 1 |
| Larson, DE | 1 |
| Brown, WM | 1 |
| Paul, KM | 1 |
| Schaper, A | 1 |
| Green, RM | 1 |
| Burwen, DR | 1 |
| Galusha, DH | 1 |
| Lewis, JM | 1 |
| Bedinger, MR | 1 |
| Radford, MJ | 2 |
| Krumholz, HM | 2 |
| Foody, JM | 1 |
| McCall, AL | 1 |
| McLeod, AL | 1 |
| Brooks, L | 1 |
| Taylor, V | 1 |
| Currie, PF | 1 |
| Dewhurst, NG | 1 |
| Sheridan, SL | 1 |
| Lee, YZ | 1 |
| Kuo, J | 1 |
| Phillips, C | 1 |
| Zeiger, R | 1 |
| Solenski, NJ | 1 |
| Pabst, S | 1 |
| Vetter, H | 1 |
| Weisser, B | 1 |
| Düsing, R | 1 |
| Fulcher, GR | 1 |
| Amarena, JV | 1 |
| Conner, GW | 1 |
| Gilbert, RE | 1 |
| Smaha, LA | 1 |
| Malcolm, J | 3 |
| Meggison, H | 2 |
| Sigal, R | 3 |
| Hacke, W | 1 |
| Marissal, JP | 1 |
| Sailly, JC | 1 |
| Crainich, D | 1 |
| Lebrun, T | 1 |
| Haines, ST | 1 |
| Fuke, DC | 1 |
| Lender, D | 1 |
| Rodgers, PT | 1 |
| Sysko, SK | 1 |
| Gami, A | 1 |
| Arnaout, A | 1 |
| Blonde, L | 1 |
| Dempster, J | 1 |
| Gallivan, JM | 1 |
| Warren-Boulton, E | 1 |
| Kotake, H | 1 |
| Oikawa, S | 1 |
| Desch, S | 1 |
| Schuler, G | 1 |
| Niebauer, J | 1 |
| Masanauskiene, E | 1 |
| Naudziūnas, A | 1 |
| Shrivastava, R | 1 |
| Khan, A | 1 |
| Jeevanantham, V | 1 |
| Nautiyal, A | 1 |
| Garg, P | 1 |
| Reddy, PC | 1 |
| Wielgosz, AT | 1 |
| Fitch, LL | 1 |
| Buchwald, H | 1 |
| Matts, JP | 1 |
| Johnson, JW | 1 |
| Campos, CT | 1 |
| Long, JM | 1 |
| Kerr, CP | 1 |
| Rångemark, C | 1 |
| Ciabattoni, G | 1 |
| Wennmalm, A | 1 |
| Yudkin, JS | 1 |
| Hoffmann, U | 1 |
| Leu, AJ | 1 |
| Golden, WE | 1 |
| Sanchez, N | 1 |
| Sharpe, N | 1 |
| Gascón Ramón, G | 1 |
| Bertomeu i Blanch, F | 1 |
| Baño Aracil, M | 1 |
| Madrigal, JA | 1 |
| Berger, AK | 1 |
| Edris, DW | 1 |
| Breall, JA | 1 |
| Oetgen, WJ | 1 |
| Marciniak, TA | 1 |
| Molinari, GF | 1 |
| Mehta, RH | 1 |
| Smith, SC | 1 |
| Campbell, NC | 2 |
| Thain, J | 2 |
| Deans, HG | 2 |
| Ritchie, LD | 2 |
| Rawles, JM | 2 |
| Vaidya, JS | 1 |
| FitzGerald, GA | 1 |
| Charman, WN | 1 |
| Asirvatham, S | 1 |
| Sebastian, C | 1 |
| Thadani, U | 1 |
| Squair, JL | 1 |
| Morrison, CE | 1 |
| McMurray, JJ | 1 |
| Turner-Boutle, M | 1 |
| Sheldon, T | 1 |
| Smith, GD | 1 |
| Ebrahim, S | 1 |
| Chowdhury, TA | 1 |
| Lasker, SS | 1 |
| Dyer, PH | 1 |
| Dobson, AJ | 1 |
| McElduff, P | 1 |
| Heller, R | 1 |
| Alexander, H | 1 |
| Colley, P | 1 |
| D'Este, K | 1 |
| McMullan, MR | 1 |
| Caramaschi, P | 1 |
| Biasi, D | 1 |
| Volpe, A | 1 |
| Carletto, A | 1 |
| Bambara, LM | 1 |
| Birkeland, KI | 1 |
| Claudi, T | 1 |
| Hansteen, V | 1 |
| Hanssen, KF | 1 |
| Hjermann, I | 1 |
| Jenssen, T | 1 |
| Jervell, J | 1 |
| Os, I | 1 |
| Drouganis, A | 1 |
| Hirsch, R | 1 |
| Cohen, JD | 1 |
| Druss, BG | 1 |
| Bradford, WD | 1 |
| Rosenheck, RA | 1 |
| Walters, MR | 1 |
| Lees, KR | 1 |
| Bratzler, DW | 1 |
| Oehlert, WH | 1 |
| Walkingstick, K | 1 |
| Murray, CK | 1 |
| Shook, C | 1 |
| Kiberd, BA | 1 |
| Bundlie, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease[NCT02646488] | 276 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| "RCT of an Intervention to Enable Stroke Survivors in Los Angeles County Hospitals to Stay Within the Guidelines (SUSTAIN)"[NCT00861081] | 410 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Correlation Between Pulmonary Artery Doppler And Other Ultrasonographic Markers With Neonatal Outcome In Placenta Accreta Spectrum Patients[NCT04911322] | 71 participants (Actual) | Observational | 2021-08-15 | Completed | |||
| Correlation Between Pulmonary Artery Doppler And Neonatal Outcome In Hypertensive Disorders Of Pregnancy[NCT05793125] | 72 participants (Anticipated) | Observational | 2023-04-03 | Recruiting | |||
| Midwest Small Practice Care Transformation Research Alliance (MSPCTRA)[NCT02598284] | 226 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769] | Phase 1 | 9 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study[NCT01480804] | 48 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Identifying and Overcoming Barriers to Diabetes Management in the Elderly: A Cost-effective Intervention Study[NCT01486290] | 52 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| [NCT00000490] | Phase 3 | 0 participants | Interventional | 1973-06-30 | Completed | ||
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
33 reviews available for aspirin and Smoking Cessation
| Article | Year |
|---|---|
Reducing Tobacco-Related Disability in Chronic Smokers.
Topics: Aortic Aneurysm, Abdominal; Aspirin; Cardiovascular Diseases; Cigarette Smoking; Early Detection of | 2020 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy.
Topics: Aspirin; Biomarkers; Canada; Consensus; Evidence-Based Medicine; Female; Fetal Growth Retardation; F | 2018 |
Prevention of Prematurity: Advances and Opportunities.
Topics: Anti-Infective Agents; Aspirin; Cerclage, Cervical; Cesarean Section; Female; Humans; Indomethacin; | 2018 |
Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.
Topics: Aspirin; Belgium; Cardiovascular Diseases; Cost-Benefit Analysis; Health Policy; Humans; Hydroxymeth | 2009 |
Is it worth offering cardiovascular disease prevention to the elderly?
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Diet; Exercise; Hu | 2013 |
[Asthma exacerbations: pharmacological prevention].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Anti-Asthmatic Agent | 2012 |
Cardiovascular disorders. Primary prevention.
Topics: Aspirin; Benzofurans; Cardiovascular Diseases; Combined Modality Therapy; Exercise; Feeding Behavior | 2002 |
A benefit-risk assessment of agents used in the secondary prevention of stroke.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Aspirin; Clinical | 2002 |
[Secondary prevention after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 2002 |
Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force.
Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Evidence-Based Medicine; E | 2003 |
Cardiovascular disorders. Primary prevention.
Topics: Aspirin; Benzofurans; Cardiovascular Diseases; Combined Modality Therapy; Exercise; Feeding Behavior | 2002 |
Transient ischemic attacks: Part II. Treatment.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Aspirin; Female; | 2004 |
[Thromboangiitis obliterans (M. Winiwarter-Buerger). Main symptoms: acral cyanosis and aches].
Topics: Adult; Analgesics, Opioid; Angiography, Digital Subtraction; Antihypertensive Agents; Aspirin; Calci | 2004 |
Prevention of cardiovascular disease: an evidence-based clinical aid 2004.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiova | 2004 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Corona | 2003 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Corona | 2004 |
Secondary prevention of ischaemic cardiac events.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2006 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopid | 2006 |
Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education Program.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; | 2006 |
[Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Dyslipidemias; Humans; Hy | 2006 |
[Conservative treatment of coronary heart disease--current options].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Body Mass Index; Cho | 2005 |
[Peripheral arterial disease--an underappreciated clinical problem].
Topics: Age Factors; Aged; Ankle; Aspirin; Atherosclerosis; Brachial Artery; Diabetes Complications; Dyslipi | 2008 |
What do we really know about secondary prevention after myocardial infarction?
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Competence; Humans; Life Style; Myocardial Infarction | 1995 |
Eight underused prescriptions.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Antidepressive Agents; Aspirin; Dietary Fiber | 1994 |
How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects.
Topics: Adult; Aspirin; Blood Pressure; Coronary Disease; Diabetes Mellitus; England; Humans; Hypercholester | 1993 |
[Secondary prevention of arteriosclerosis].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Aspirin; Humans; Hypoglycemic A | 1996 |
[Intervention in risk factors and protection of target organs].
Topics: Alcohol Drinking; Aspirin; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Est | 1997 |
Secondary prevention in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1998 |
Risk reduction therapies for patients with coronary artery disease: a call for increased implementation.
Topics: Adrenergic beta-Antagonists; American Heart Association; Angiotensin-Converting Enzyme Inhibitors; A | 1998 |
Choosing the most appropriate treatment for stable angina. Safety considerations.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspiri | 1998 |
Royal College of Physicians of Edinburgh Consensus Conference on lipid lowering to prevent vascular events 17 & 18 March 1999.
Topics: Adult; Aged; Aspirin; Cholesterol; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis | 1999 |
[Prevention of cardiovascular disease in type 2 diabetes].
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dietary Servic | 2000 |
Cardiovascular risk reduction in renal transplantation. Strategies for success.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Cost-Benefit | 2002 |
9 trials available for aspirin and Smoking Cessation
| Article | Year |
|---|---|
Cardiovascular Disease Guideline Adherence: An RCT Using Practice Facilitation.
Topics: Aspirin; Blood Pressure; Cardiovascular Diseases; Cholesterol; Goals; Guideline Adherence; Health Be | 2020 |
Quality of Cardiovascular Disease Care in Small Urban Practices.
Topics: Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Delivery of Health Care; Guideline Adhere | 2018 |
Design of healthy hearts in the heartland (H3): A practice-randomized, comparative effectiveness study.
Topics: Adult; Aspirin; Blood Pressure Determination; Cardiovascular Diseases; Female; Health Facility Size; | 2018 |
Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Aspirin; Cerebrovascular Disorders; Cost-Benefi | 2009 |
Reducing CVD risk in type 2 DM.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
Effect of aspirin use on death and recurrent myocardial infarction in current and former cigarette smokers. Program on the Surgical Control of the Hyperlipidemias Group.
Topics: Aspirin; Cohort Studies; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypercholestero | 1995 |
Interpretation of Thrombosis Prevention Trial.
Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Humans; Male; Myocardial Ischemia; Smoking; Smoking Ce | 1998 |
Interpretation of Thrombosis Prevention Trial.
Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Humans; Life Style; Male; Myocardial Ischemia; Risk Fa | 1998 |
Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care.
Topics: Aged; Ambulatory Care Facilities; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease | 1998 |
68 other studies available for aspirin and Smoking Cessation
| Article | Year |
|---|---|
Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex.
Topics: Aspirin; Benchmarking; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cross-Sectional Studies | 2023 |
Derivation and Application of a Tool to Estimate Benefits From Multiple Therapies That Reduce Recurrent Stroke Risk.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Aspirin; Diet Therapy; Exer | 2020 |
Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Trea
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2017 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula | 2017 |
The New 2019 AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease.
Topics: American Heart Association; Aspirin; Cardiology; Cardiovascular Diseases; Consensus; Diet, Healthy; | 2020 |
Clopidogrel use and smoking cessation result in lower coated-platelet levels after stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Drug | 2020 |
Tips for GP trainees working in vascular surgery.
Topics: Anticholesteremic Agents; Aspirin; Blood Pressure; Clinical Competence; Clopidogrel; Education, Medi | 2014 |
Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.
Topics: Aged; Amputation, Surgical; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Guideline Adh | 2014 |
Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2014 |
Pirfenidone for idiopathic pulmonary fibrosis, thrombocytosis in chronic obstructive pulmonary disease exacerbations, and a longitudinal study on e-cigarettes.
Topics: Antifibrinolytic Agents; Aspirin; Drug Delivery Systems; Enzyme Inhibitors; Female; Humans; Idiopath | 2014 |
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2015 |
Assessing Diabetes Care Disparities with Ambulatory Care Quality Measures.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Aspirin; Cholesterol, LDL; Diabetes Mellitus; Electronic H | 2015 |
Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; California; Female; Guideline Adherence; Hu | 2015 |
[39-year-old man with 15 years lasting pain in both hands].
Topics: Administration, Oral; Adult; Aspirin; Chronic Pain; Diagnosis, Differential; Hand; Hematopoietic Ste | 2015 |
Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiot | 2016 |
Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2016 |
ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction.
Topics: Antihypertensive Agents; Aspirin; Catheter Ablation; Clopidogrel; Combined Modality Therapy; Electro | 2009 |
Theophylline again? Reasons for believing.
Topics: Anti-Inflammatory Agents; Aspirin; Asthma; Bronchodilator Agents; Humans; Inflammation; Phosphoric D | 2009 |
Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Biomarkers; Blood Pressure; Cardio | 2009 |
Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Bl | 2009 |
Evidence of disparity in the application of quality improvement efforts for the treatment of acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice Initiative in Michigan.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Counseling; Drug Pres | 2010 |
[Stroke: women have a different risk profile].
Topics: Aspirin; Contraceptive Agents, Female; Diabetes Complications; Education; Exercise; Female; Hormones | 2010 |
Hospitals with percutaneous coronary intervention capability have greater adherence to established myocardial infarction guidelines.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers | 2010 |
Ischaemic stroke--prevention is better than cure.
Topics: Adult; Age Factors; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Blo | 2010 |
Early aggressive medical management for patients with symptomatic intracranial stenosis.
Topics: Aged; Antihypertensive Agents; Aspirin; Biomarkers; Blood Pressure; Body Mass Index; Cerebral Angiog | 2013 |
What the million hearts initiative means for stroke: a presidential advisory from the American Heart Association/American Stroke Association.
Topics: American Heart Association; Aspirin; Blood Pressure; Cardiovascular Diseases; Centers for Disease Co | 2012 |
Revisiting cerebral thromboangiitis obliterans.
Topics: Aspirin; Female; Humans; Middle Aged; Smoking; Smoking Cessation; Thromboangiitis Obliterans | 2012 |
The Million Hearts™ initiative: why psychosocial nurses should care.
Topics: Aspirin; Cholesterol; Comorbidity; Health Promotion; Humans; Hypertension; Mental Disorders; Myocard | 2012 |
Buerger's disease (Thromboangiitis obliterans): a diagnostic challenge.
Topics: Adult; Angiography; Aspirin; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Hepa | 2011 |
Reducing the cardiovascular disease burden: justified means for getting to the end.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Evidence-Based Medicine; Health Policy; H | 2012 |
Performance measures in million hearts: 2 partners' perspective.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Endpoint Determination; Evidence-Based Me | 2012 |
Million hearts--where population health and clinical practice intersect.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clinical Competence; Endpoint Determinati | 2012 |
Intestinal ischaemia and mesenteric necrosis in a heavy smoker.
Topics: Abdominal Pain; Aspirin; Diarrhea; Humans; Jejunal Diseases; Male; Mesenteric Arteries; Middle Aged; | 2013 |
The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions.
Topics: Aged; Amputation, Surgical; Aspirin; Blue Cross Blue Shield Insurance Plans; Chi-Square Distribution | 2012 |
[Peripheral arterial occlusive disease. Symptoms, basic diagnosis and staged therapy].
Topics: Amputation, Surgical; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Exercise; Humans; | 2002 |
How to keep chest pain from cramping your style. If you are one of the millions of Americans for whom chest pain is part of daily life, here are some ABCs for getting it under control.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Aspirin; Chest Pain; Diet; Exercise; Fema | 2002 |
Program improves compliance with heart attack guidelines.
Topics: Adrenergic beta-Antagonists; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronar | 2002 |
Heart attack and stroke prevention guidelines emphasize lifestyle factors.
Topics: Adult; Age Factors; American Heart Association; Aspirin; Diabetes Mellitus, Type 2; Diet; Exercise; | 2002 |
Guidelines for improving the care of the older person with diabetes mellitus.
Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M | 2003 |
Guidelines for improving the care of the older person with diabetes mellitus.
Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M | 2003 |
Guidelines for improving the care of the older person with diabetes mellitus.
Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M | 2003 |
Guidelines for improving the care of the older person with diabetes mellitus.
Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M | 2003 |
Using a systemwide care path to enhance compliance with guidelines for acute myocardial infarction.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Benchmarking; Cardiology Service, Hospital; Cli | 2003 |
National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin-Co | 2003 |
Secondary prevention for coronary artery disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cholesterol; Coronary Artery Disease; Drug | 2004 |
Heart to Heart: a computerized decision aid for assessment of coronary heart disease risk and the impact of risk-reduction interventions for primary prevention.
Topics: Adult; Antihypertensive Agents; Aspirin; Coronary Disease; Diagnosis, Computer-Assisted; Female; Hum | 2004 |
The American Heart Association Get With The Guidelines program.
Topics: Adrenergic beta-Antagonists; American Heart Association; Angiotensin-Converting Enzyme Inhibitors; A | 2004 |
[Female, young, healthy. ASS does not protect from myocardial infarct].
Topics: Adult; Age Factors; Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Placebos; Platelet A | 2005 |
[Prophylaxis of stroke].
Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi | 2005 |
[Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France].
Topics: Adolescent; Adult; Aged; Aspirin; Biguanides; Cerebrovascular Disorders; Coronary Disease; Cost-Bene | 2005 |
Evaluating and treating cardiometabolic risk factors: a case discussion.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diet; Dyslipidemias; Exercise; Female; Heart Dise | 2006 |
Control of cardiovascular risk factors and use of aspirin in diabetic patients remain elusive.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Albuminuria; Aspirin; Blood Pressure; Chol | 2008 |
Excretion of thromboxane metabolites in healthy women after cessation of smoking.
Topics: Administration, Oral; Adult; Aspirin; Cotinine; Creatinine; Female; Humans; Middle Aged; Smoking; Sm | 1993 |
The cooperative cardiovascular project an AFMC special report.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Arkansas; Aspirin; Combined Modality Th | 1996 |
Medical management after myocardial infarction: an evidence-based perspective.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as T | 1996 |
Resource use and quality of care for Medicare patients with acute myocardial infarction in Maryland and the District of Columbia: analysis of data from the Cooperative Cardiovascular Project.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; District of Columbia; Drug Utilization; Female; Health S | 1998 |
Secondary prevention in coronary heart disease: baseline survey of provision in general practice.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood P | 1998 |
On the horizon: newly-developed quality improvement projects. Florida Medical Quality Assurance, Inc.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1998 |
Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cohort Studies; Coronary | 1999 |
On the evidence. Cholesterol and coronary heart disease screening & treatment.
Topics: Antihypertensive Agents; Aspirin; Cholesterol; Cholesterol, Dietary; Coronary Disease; Cost-Benefit | 1998 |
Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; | 1999 |
Changing patterns of coronary heart disease in the hunter region of New South Wales, Australia.
Topics: Adult; Age Distribution; Aged; Aspirin; Blood Pressure; Coronary Disease; Female; Hospitalization; H | 1999 |
The ABC's of AMI.
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Choleste | 2000 |
[Aspects of thrombophilia in Buerger's disease].
Topics: Adjuvants, Immunologic; Adult; Angiography; Aspirin; Female; Humans; Hyperhomocysteinemia; Iloprost; | 2000 |
Low-dose aspirin therapy and periodontal attachment loss in ex- and non-smokers.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; | 2001 |
ABCs of secondary prevention of CHD: easier said than done.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Aspirin; Coronary Disease; Diet; Exercise; Hu | 2001 |
Quality of medical care and excess mortality in older patients with mental disorders.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C | 2001 |
Transient ischaemic attacks: a GP guide.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Carotid Arteries; Diagnosis, Differentia | 2001 |
Care of acute myocardial infarction in Oklahoma: an update from the Cooperative Cardiovascular Project.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Bloc | 2001 |
GAP program improves patients' quality of care.
Topics: Adrenergic beta-Antagonists; Aspirin; Case Management; Critical Pathways; Humans; Myocardial Infarct | 2002 |
Ischemic stroke. How to keep the first one from happening.
Topics: Aspirin; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; I | 1991 |